Gene Bridges licenses recombineering technology to Daiichi Sankyo
7 April 2009
Heidelberg-based Gene Bridges GmbH, has licenced its Red/ET
recombination technology to Daiichi Sankyo Co Ltd of Tokyo, Japan.
The Red/ET recombination technology, patented in Japan under the
title 'Novel DNA Cloning Method', is a valued method for generating
targeting vectors or modifying E. coli chromosomes.
“We are very pleased to welcome another major Japanese pharmaceutical
company as a licensee of Red/ET,” commented Gary Stevens, CEO of Gene
Bridges GmbH. “Recombineering is becoming the technology of choice in
DNA engineering and with the help of Daiichi Sankyo Co Ltd, we expect to
gain further acceptance of Red/ET in industry and academia worldwide.”
Red/ET is a revolutionary method for DNA engineering. Recombineering
with Red/ET allows cloning, subcloning, and modification of DNA at any
chosen position. It permits precise engineering of DNA molecules of any
size, including very large ones such as BACs or the E. coli
chromosome.
Bookmark this page